InNexus Biotechnology Develops New Psoriasis Treatment Product

Strategic Insights -

Scientists at InNexus Biotechnology have designed a novel antibody product, IXSCD11a, aimed at treating psoriasis, an autoimmune skin disease, using the company's proprietary dermal permeating Transmab technology. The product is being formulated for topical use and has shown significant increase in cell penetration compared to other products targeting psoriasis. The antibody fragment, IXSCD11a, binds to the CD11a receptor involved in inflammation, which is a key factor in the development of psoriasis. The company aims to develop a safe and effective treatment for the disease, which affects 125 million people worldwide.

Key Takeaways:

  • InNexus Biotechnology has developed a new psoriasis treatment product, IXSCD11a, using its proprietary Transmab technology.
  • IXSCD11a is an antibody fragment that penetrates cell membranes and dermal barriers, increasing cell penetration compared to other products targeting psoriasis.
  • The product binds to the CD11a receptor involved in inflammation, a key factor in psoriasis development.
  • IXSCD11a is designed to circumvent the systemic immune suppression side effect of full-length antibodies, with a half-life of three hours compared to 18-24 days for full-length antibodies.
  • The company aims to develop a safe and effective treatment for psoriasis, which affects 125 million people worldwide.
  • Psoriasis is the most prevalent autoimmune disease in the U.S., affecting 7.5 million people.
  • InNexus Biotechnology has a strong pipeline of products, including DXL, and has in-house developmental and manufacturing facilities.
  • The company is committed to developing treatments for autoimmune diseases that cause physical and mental suffering to millions of people.

Statistics:

  • 125 million people worldwide are affected by psoriasis (2-3% of total population).
  • 7.5 million people in the U.S. are affected by psoriasis.
  • 125 million people worldwide are affected by psoriasis, making it the most prevalent autoimmune disease in the world.
  • 7.5 million people in the U.S. are affected by psoriasis, which is present in all racial groups in varying rates.
  • 2009 was a year of survival for biotech companies, but 2010 is a year for differentiation and showing value.

Sources:

  • InNexus Biotechnology Inc. website: www.ixsbio.com
  • Biotech Week editors: This article was prepared by Biotech Week editors from staff and other reports.
  • National Psoriasis Foundation: http://www.psoriasis.org